Danileviciūte Vita
Vilniaus universiteto Psichiatrijos klinika, Valstybinis psichikos sveikatos centras, Parko 15, 2048 Vilnius.
Medicina (Kaunas). 2002;38(11):1057-65.
During 20th century serious mental disorders were divided into two groups according symptomatology and course of disorder. Individuals with dominating disturbance of perception, thinking and cognition were basically diagnosed having schizophrenic. Individuals with mood disturbance were basically diagnosed having affective disorders. However, there were patients who did not fit neatly into either category. In 1933 Jocob Kasanin introduced the term "schizoaffective psychosis". Scientific discussions involved the possibility that schizoaffective disorder was conceptualized most accurately as following: a type of schizophrenia, a type of affective disorder, a unique disorder that was separate from both schizophrenia and bipolar disorder, an arbitrary categorization of clinical symptoms that marked a continuum between schizophrenia and affective illness, a heterogeneous collection of "interforms" between schizophrenia and affective disorders. However, diagnosis of schizoaffective disorder is included both in DSM-IV-TR and ICD-10. Schizoaffective disorder is listed in the category "schizophrenia and other psychotic disorders". The differential diagnosis includes basically either schizophrenia or affective disorder. The epidemiological status of schizoaffective disorder is somewhat uncertain compared with schizophrenia because of dilemmas related to diagnosis and classification of the disorder. Treatment of schizoaffective disorder comprises psychotropic medication, supportive psychotherapy, social care, rehabilitation. The most important groups of psychotropic medications are: antipsychotics, antidepressants and mood stabilizers. Atypical antipsychotics are the first-line medication for schizoaffective disorder due to their pharmacological properties. In the case of schizoaffective disorders combination of atypical antipsychotics with antidepressants seems to be useful. Novel antidepressants have priority for the combination mentioned above. Peculiarities of mechanism of action of antidepressant are important for combinations. Mood stabilizers seem to be useful for treatment of certain type of schizoaffective disorder as well.
在20世纪,严重精神障碍根据症状学和病程被分为两组。以感知、思维和认知障碍为主的个体基本上被诊断为患有精神分裂症。以情绪障碍为主的个体基本上被诊断为患有情感障碍。然而,有一些患者并不完全符合这两类中的任何一类。1933年,雅各布·卡沙宁引入了“分裂情感性精神病”这一术语。科学讨论涉及以下可能性:分裂情感性障碍最准确的概念化方式如下:一种精神分裂症类型、一种情感障碍类型、一种独立于精神分裂症和双相情感障碍的独特障碍、一种标志着精神分裂症和情感性疾病之间连续体的临床症状的任意分类、精神分裂症和情感障碍之间“中间形式”的异质性集合。然而,分裂情感性障碍的诊断既包括在《精神疾病诊断与统计手册》第四版修订版(DSM-IV-TR)中,也包括在《国际疾病分类》第十版(ICD-10)中。分裂情感性障碍被列在“精神分裂症及其他精神病性障碍”类别中。鉴别诊断基本上包括精神分裂症或情感障碍。与精神分裂症相比,由于该障碍在诊断和分类方面存在困境,分裂情感性障碍的流行病学状况有些不确定。分裂情感性障碍的治疗包括精神药物治疗、支持性心理治疗、社会关怀和康复。最重要的精神药物类别是:抗精神病药物、抗抑郁药物和心境稳定剂。非典型抗精神病药物因其药理特性是分裂情感性障碍的一线用药。在分裂情感性障碍的情况下,非典型抗精神病药物与抗抑郁药物联合使用似乎是有用的。新型抗抑郁药物在上述联合使用中具有优先地位。抗抑郁药物作用机制的特殊性对于联合使用很重要。心境稳定剂似乎对某些类型的分裂情感性障碍的治疗也有用。